TROSPIUM CHLORIDE VERSUS TAMSULOSIN IN THE TREATMENT OF DOUBLE-J STENT RELATED LOWER URINARY TRACT SYMPTOMS (LUTS)

Authors

  • V. D. RADU Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania
  • P. ONOFREI Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania
  • Andreea LUDUSANU Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania
  • Ana-Maria Raluca PAUNA Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania
  • S. B. DIEACONU Dr. C. I. Parhon University Hospital, Iasi, Romania
  • T. F. PANTILIMONESCU Dr. C. I. Parhon University Hospital, Iasi, Romania
  • Rodica RADU Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania

DOI:

https://doi.org/10.22551/

Abstract

Double-J ureteral stents frequently cause lower urinary tract symptoms (LUTS), including urinary urgency and pollakiuria, which significantly affect patient comfort. This study compared the efficacy and safety of trospium chloride versus tamsulosin in patients with stent-related LUTS. Materials and methods: We conducted a retrospective 6-year study comparing patients with LUTS in the presence of double-J stents who had received trospium for 4 weeks (39 patients) with patients who had received tamsulosin (52 patients). Results: Both trospium and tamsulosin relieved LUTS symptoms (p<0.05). Trospium relieved pollakiuria (82.05% vs. 61.53%, p=0.034) and urinary urgency (87.17% vs. 59.61%, p=0.003) in a higher percentage than tamsulosin. However, there was no statistically significant difference in the improvement of urinary urgency incontinence (80% vs. 47.05%, not significant at p<0.05), hypogastric pain (64% vs. 40%, p=0.103), foreign body sensation (64.28% vs. 38.09%, p=0.128) and macroscopic hematuria (37.5% vs. 18.18%, not significant at p < 0.05); side effects occurred rarely, with no statistically significant difference between the two groups (5.12% vs. 5.76%, not significant at p<0.05). Conclusions: Trospium chloride is a safe and effective option for managing LUTS associated with double-J stents and provides superior improvement in pollakiuria and urinary urgency compared with tamsulosin.

Author Biographies

  • V. D. RADU, Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania

    Dr. C. I. Parhon University Hospital, Iasi, Romania

  • P. ONOFREI, Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania

    Elytis Hope Hospital, Iasi, Romania

  • S. B. DIEACONU, Dr. C. I. Parhon University Hospital, Iasi, Romania

    Double-J ureteral stents frequently cause lower urinary tract symptoms (LUTS), including urinary urgency and pollakiuria, which significantly affect patient comfort. This study compared the efficacy and safety of trospium chloride versus tamsulosin in patients with stent-related LUTS. Materials and methods: We conducted a retrospective 6-year study comparing patients with LUTS in the presence of double-J stents who had received trospium for 4 weeks (39 patients) with patients who had received tamsulosin (52 patients). Results: Both trospium and tamsulosin relieved LUTS symptoms (p<0.05). Trospium relieved pollakiuria (82.05% vs. 61.53%, p=0.034) and urinary urgency (87.17% vs. 59.61%, p=0.003) in a higher percentage than tamsulosin. However, there was no statistically significant difference in the improvement of urinary urgency incontinence (80% vs. 47.05%, not significant at p<0.05), hypogastric pain (64% vs. 40%, p=0.103), foreign body sensation (64.28% vs. 38.09%, p=0.128) and macroscopic hematuria (37.5% vs. 18.18%, not significant at p < 0.05); side effects occurred rarely, with no statistically significant difference between the two groups (5.12% vs. 5.76%, not significant at p<0.05). Conclusions: Trospium chloride is a safe and effective option for managing LUTS associated with double-J stents and provides superior improvement in pollakiuria and urinary urgency compared with tamsulosin.

References

1. Höfner K, Oelke M, Machtens S, Grünewald V. Trospium chloride-An effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001; 19: 336-343.

2. Guay DR. Trospium chloride: An update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag 2005; 1: 157-167.

3. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: A multicenter phase III trial. J Urol 2004; 171: 2311-2315.

4. Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother 2009; 43: 283-295.

5. Singh-Franco D, Machado C, Tuteja S, Zapantis A. Trospium chloride for the treatment of overactive bladder with urge incontinence. Clin Ther 2005; 27: 511-530.

6. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004; 64: 2433-2446.

7. Korshunova ES, Andreev MN, Korshunov MN, et al. Long-term safety and efficacy of trospium chloride for neurogenic overactive bladder due to Parkinson’s disease: Is there an effect on cognitive status? Urologiia 2022; 6: 71-77.

8. Zinner NR. Trospium chloride: An anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin Pharmacother 2005; 6: 1409-1420.

9. Zinner NR, Dmochowski RR, Staskin DR, Siami PF, Sand PK, Oefelein MG. Once-daily trospium chloride 60 mg extended-release provides long-term relief of overactive bladder symptoms. Neurourol Urodyn 2011; 30: 1214-1219.

10. Dmochowski RR, Rosenberg MT, Zinner NR, Staskin DR, Sand PK. Extended-release trospium chloride improves quality of life in overactive bladder. Value Health 2010; 13: 251-257.

11. Chapple C. New once-daily formulation for trospium in overactive bladder. Int J Clin Pract 2010; 64: 1535-1540.

12. Srivastava VK, Agrawal S, Deshmukh SA, Noushad F, Khan S, Kumar R. Efficacy of trospium for prevention of catheter-related bladder discomfort: A randomized, placebo-controlled, double-blind study. Korean J Anesthesiol 2020; 73: 145-150.

13. Radu VD, Costache RC, Onofrei P, et al. Urinary tract infections with carbapenem-resistant Klebsiella pneumoniae in a urology clinic. A case-control study. Antibiotics (Basel) 2024; 13: 583.

14. Miftode IL, Vâță A, Miftode RȘ, et al. The impact of urinary catheterization on the antibiotic susceptibility of ESBL-producing Enterobacterales. Antibiotics (Basel) 2024; 13: 462.

15. Radu VD, Ristescu C, Tomac I, Radu R, Onofrei P, Costache RC. Does long preoperative double-J stenting influence outcomes of retrograde ureteroscopy for ureteral stones? Med-Surg J - Rev Med Chir Soc Med Nat Iasi 2021; 125: 274-279.

16. Radu VD, Costache RC, Onofrei P, et al. Double-J ureteral stenting in obstetrics and gynecology: Pivotal or problematic? J Clin Med 2024; 13: 7649.

17. Wang CJ, Huang SW, Chang CH. Effects of specific α-1A/1D blocker on lower urinary tract symptoms due to double-J stent: A randomized study. Urol Res 2009; 37: 147-152.

18. Madersbacher H, Mürtz G, Stöhrer M. Neurogenic detrusor overactivity in adults: Efficacy and safety of oral antimuscarinics. Spinal Cord 2013; 51: 432-441.

19. Johnson TM 2nd, Goode PS, Hammontree L, et al. An exploratory analysis of tamsulosin for overactive bladder in men with varying voiding symptom burden. Urology 2021; 153: 42-48.

20. Shalaby E, Ahmed AF, Maarouf A, Yahia I, Ali M, Ghobish A. Randomized controlled trial to compare tamsulosin, solifenacin, and combination therapy in double-J stent-related LUTS. Adv Urol 2013; 2013: 752382.

21. Staskin DR. Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am 2006; 33: 465-473.

22. Duong V, Iwamoto A, Pennycuff J, et al. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J 2021; 32: 2693-2702.

23. Murgas S, Adolf D. Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany. Res Rep Urol 2019; 11: 9-13.

24. Miftode L, Bădescu A, Miftode E, Prepeliuc CS, Dorneanu O. The impact of ESBL-producing Enterobacterales: An old story with new perspectives. Med-Surg J - Rev Med Chir Soc Med Nat Iasi 2022; 126: 204-213.

25. Turkoglu AR, Parmak Yener N, Coban S, et al. Effect of trospium chloride therapy on intraocular pressure and tear secretion in overactive bladder patients. Cutan Ocul Toxicol 2017; 36: 331-335.

26. Madersbacher H, Rovner E. Trospium chloride: The European experience. Expert Opin Pharmacother 2006; 7: 1373-1380.

27. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006; 67: 275-280.

28. Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of anti-muscarinics for treating overactive bladder: Network meta-analyses. Eur Urol 2012; 62: 1040-1060.

29. Bödeker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: Post hoc analysis of a multicentre, double-blind, parallel-group trial of trospium chloride. BMC Urol 2010; 10: 15.

30. Brostrøm S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009; 65: 309-314.

31. Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60 mg extended-release in subjects with overactive bladder using multiple concomitant medications: A post hoc pooled analysis. Drugs Aging 2011; 28: 151-160.

32. Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥50 years. BJU Int 2005; 95: 346-349.

33. Dmochowski RR, Newman DK, Rovner ES, Zillioux J, Malik RD, Ackerman AL. Patient and clinician challenges with anticholinergic step therapy in the treatment of overactive bladder: A narrative review. Adv Ther 2023; 40: 4741-4757.

Additional Files

Published

2026-04-01

Issue

Vol. 130 No. 1 (2026): The Medical-Surgical Journal

Section

SURGERY

License

Copyright (c) 2026 The Medical-Surgical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form